Jagsonpal Pharma

64
Hold
  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE048B01035
  • NSEID: JAGSNPHARM
  • BSEID: 507789
INR
232.55
-5.05 (-2.13%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 74.93 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 28.76% vs -11.83% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 121.40% vs -32.46% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 17.69% vs 97.09% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 146.45% vs -15.94% in Mar 2024

Compare Profit and Loss Results of Jagsonpal Pharma
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
268.00
450.00
-182.00
-40.44%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
268.00
450.00
-182.00
-40.44%
Expenditure (Ex Depriciation)
Stock Adjustments
-2.00
-24.00
22.00
91.67%
Raw Materials Consumed
98.00
178.00
-80.00
-44.94%
Power & Fuel Cost
0.00
29.00
-29.00
-100.00%
Employee Cost
70.00
74.00
-4.00
-5.41%
Operating Expenses
0.00
45.00
-45.00
-100.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
24.00
16.00
8.00
50.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
8.00
-8.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
217.00
358.00
-141.00
-39.39%
Operating Profit (PBDIT) excl Other Income
51.00
91.00
-40.00
-43.96%
Other Income
8.00
23.00
-15.00
-65.22%
Operating Profit (PBDIT)
59.00
115.00
-56.00
-48.70%
Interest
0.00
12.00
-12.00
-100.00%
Profit before Depriciation and Tax
58.00
103.00
-45.00
-43.69%
Depreciation
8.00
20.00
-12.00
-60.00%
Profit Before Taxation & Exceptional Items
50.00
82.00
-32.00
-39.02%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
69.00
89.00
-20.00
-22.47%
Provision for Tax
14.00
24.00
-10.00
-41.67%
Profit After Tax
55.00
64.00
-9.00
-14.06%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
104.00
340.00
-236.00
-69.41%
Profit Available for appropriations
159.00
404.00
-245.00
-60.64%
Appropriations
159.00
404.00
-245.00
-60.64%
Equity Dividend (%)
125%
75%
50.00
Earnings Per Share
8.26
22.13
-13.87
-62.68%
Profit And Loss - Net Sales
Net Sales 268.72 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 28.76% vs -11.83% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 51.07 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 121.40% vs -32.46% in Mar 2024

Profit And Loss - Interest
Interest 0.96 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 17.69% vs 97.09% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 55.36 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 146.45% vs -15.94% in Mar 2024